A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects With Partial Onset Seizures

Ortho-McNeil Janssen Scientific Affairs, LLC0 个研究点目标入组 600 人开始时间: 2009年7月20日最近更新: 2020年4月27日

适应症

试验速览

阶段: 3 期
状态: 终止
发起方: Ortho-McNeil Janssen Scientific Affairs, LLC
入组人数: 600

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomised controlled trial
主要目的: Treatment
盲法: Blinded (masking used)

入排标准

年龄范围: 16 Years 至 o limit（—）
性别: All

入选标准

•Patients must weigh >= 45 kg (~100lbs)
•Established diagnosis, for at least 3 months prior to screening, of partial onset seizures, including simple partial motor, complex partial, or secondarily generalized seizures
•At least 1 but no more than 120 partial onset seizures during the 3-month retrospective baseline period prior to screening
•History of monotherapy Anti Epileptic Drug (AED) treatment failure at at least 1 but not more than 4 AEDs in the past
•Females must be postmenopausal for at least 2 years, surgically sterile, abstinent, or, if sexually active, practicing an acceptable method of birth control (eg, intrauterine device, double barrier method, male partner sterilization) before entry and throughout the study
•Females must have a negative serum beta chorionic gonadotropin pregnancy test result at screening/randomization
•Current AED treatment with at least 1 and no more than 2 AEDs given at a stable dose 30 days prior to screening
•For adolescents (as defined by local regulations), a responsible person must be available to accompany the patient to the study center at each visit, to provide reliable information for the safety and effectiveness evaluations, and to accurately and reliably dispense the study drug as directed, if required in the opinion of the investigator

排除标准

•Must not have a generalized epileptic syndrome, primary generalized seizures, atonic seizures, typical or atypical absence seizures nor only simple partial type seizures with manifestations other than motor symptoms (i.e, simple partial sensory)
•No history of unprovoked status epilepticus in the last 6 months prior to screening nor history of Lennox-Gastaut or West Syndrome
•More than 3 days of sedative or benzodiazepine use for seizures in the 3 months months prior to screening
•No clinical evidence of significant cardiac disease
•Alanine transaminase (ALT) > 1.5 times the upper limit of normal or total bilirubin above the upper limit of normal at screen
•No history of drug-induced liver injury, diagnosis of any form of chronic liver disease, cirrhosis, or liver cancer nor positive hepatitis serology as determined by multiantigen enzyme immunoassay (EIA)
•No past or current treatment with topiramate or levetiracetam for any reason
•No current use of vagal nerve stimulator
•No diagnosis of psychotic disorder, bipolar disease, or major depression or other neurologic conditions, serious or medically unstable systemic disease, suicidal ideation or attempts, or homicide attempts at any time in the past 2 years
•Unable to swallow solid oral dosage forms whole with the aid of water (patients may not chew, divide, dissolve, or crush the study drug)
•Anyone who falls under the precautions, warnings or contraindications outlined in the local topiramate and/or local levetiracetam package insert

研究者

发起方

Ortho-McNeil Janssen Scientific Affairs, LLC

相似试验

进行中（未招募）

不适用

EUCTR2006-005385-39-HUsanofi-aventis recherche et developpement500

进行中（未招募）

不适用

EUCTR2006-005385-39-FIsanofi-aventis recherche et developpement500

已完成

3 期

A Glycemic Control Evaluation of Glimepiride versus Rimonabant on Top of Metformin in Type 2 Diabetes

CTRI/2008/091/000040SanofiSynthelabo IndiaLtd500

进行中（未招募）

不适用

EUCTR2006-005385-39-ITsanofi-aventis recherche et developpement500

进行中（未招募）

1 期

A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess Glycemic Control with Rimonabant in Comparison with Glimepiride over 1 Year in Overweight/Obese Type 2 Diabetic Patients Not Adequately Controlled with Metformin------------------------------Estudio aleatorizado, doble ciego, con grupos paralelos, multicéntrico y multinacional para evaluar el control de la glucemia con rimonabant comparado con glimepirida durante 1 año en pacientes diabéticos tipo 2 con sobrepeso u obesidad mal controlados con metformina - ALLEGROOverweight/Obese Type 2 Diabetic Patients Not Adequately Controlled with Metformin-----------------------------Pacientes diabéticos tipo 2 con sobrepeso/obesos no adecuadamente controlados con metformina.MedDRA version: 8.1Level: LLTClassification code 10045242Term: Type II diabetes mellitus

EUCTR2006-005385-39-ESsanofi-aventis recherche et developpement500